Does Harvard Pilgrim Health Care Cover Wegovy?
The verdict
Conditional on most plans
Harvard Pilgrim Health Care's Wegovy coverage is employer-dependent and not publicly published in detail. Weight-loss coverage exists only where the employer purchased the anti-obesity benefit. The New England market context is notable: BCBS of Massachusetts ended weight-loss GLP-1 coverage in January 2026 and New Hampshire Medicaid removed GLP-1 obesity coverage in January 2026 — regional signals that Harvard Pilgrim members should verify their own plan rather than assuming coverage.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Harvard Pilgrim Health Care using your member ID.
Key facts
Blue Cross Blue Shield of Massachusetts ended weight-loss GLP-1 coverage effective January 1, 2026 — a regional signal of cost pressure that Harvard Pilgrim members in New England should factor into their coverage verification.
BCBS of Massachusetts member communications, 2025
New Hampshire Medicaid dropped GLP-1 obesity coverage effective January 1, 2026 — affecting Harvard Pilgrim NH Medicaid enrollees.
KFF — Medicaid Coverage of and Spending on GLP-1s, January 2026
The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible Medicare beneficiaries Wegovy weight-loss access at $50/month outside Part D — not counting toward the $2,100 OOP cap.
CMS.gov, Medicare GLP-1 Weight Loss Drug Access Program
Medicare vs. commercial coverage
Whether Harvard Pilgrim Health Care covers Wegovy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D cannot cover Wegovy for weight loss by statute — this applies to all Harvard Pilgrim Medicare plans. Harvard Pilgrim Medicare Advantage plans can cover Wegovy for the cardiovascular risk-reduction indication (FDA-approved for adults with established CVD who are overweight or obese) with prior authorization. The Medicare GLP-1 Bridge launches July 1, 2026, giving eligible Medicare beneficiaries weight-loss access to Wegovy at $50/month through December 31, 2027 — this operates outside Part D, so the $50 does not count toward the $2,100 OOP cap or TrOOP. Extra Help cannot be applied to Bridge copays. NovoCare savings card is not available to Medicare beneficiaries.
Commercial / Employer
Group & marketplace plans
Harvard Pilgrim commercial and employer plans cover Wegovy for weight loss only when the employer has purchased the anti-obesity benefit. Where the benefit is included, prior authorization is required: typically BMI 30 or higher, or BMI 27 or higher with a weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea), plus documented lifestyle program participation and weight-loss maintenance for renewal. If the employer did not opt in, weight-loss Wegovy is excluded — this is a benefit design decision, not a medical-necessity denial, and appeals will not succeed. ACA/individual-market plans generally exclude weight-loss Wegovy. New England regional context: Blue Cross Blue Shield of Massachusetts ended weight-loss GLP-1 coverage effective January 1, 2026 — a signal of regional cost pressure that members should weigh when verifying their own Harvard Pilgrim coverage. New Hampshire Medicaid dropped GLP-1 obesity coverage effective January 1, 2026. Per-plan drug tier and cost-share are not publicly published; verify via Harvard Pilgrim's drug-lookup tool. Commercially insured members whose plan covers Wegovy may use the NovoCare savings card at $25/month (max $100 per 28-day supply; not available to Medicare or Medicaid).
The 4 boxes you must tick to get approved
Commercial plans that will consider Wegovy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 4 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Wegovy actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
$1,349/month (Novo Nordisk published list price for a 28-day supply). NovoCare self-pay: approximately $349/month for standard injection doses after an introductory period through December 31, 2026.
List price with no coverage — before any manufacturer savings card.
With coverage
Plan-specific cost-share where covered — not publicly published at the drug level. Confirm your specific cost-share on Harvard Pilgrim's drug-lookup tool or member portal. NovoCare savings card: commercially insured Harvard Pilgrim members whose plan covers Wegovy may pay as little as $25/month (max $100 per 28-day supply). Not available to Medicare or Medicaid beneficiaries.
Typical monthly copay once prior authorization is approved.
Bridge program
Medicare GLP-1 Bridge: $50/month fixed copay for eligible Medicare beneficiaries, launching July 1, 2026, through December 31, 2027. Operates outside Part D — does not count toward the $2,100 OOP cap, TrOOP, or Extra Help. Provider must attest eligibility at initiation.
Reduced copay through the assistance program, where eligible.
All cost figures are estimates. Actual cost-share varies by plan tier, deductible phase, and pharmacy — confirm with your Harvard Pilgrim plan and pharmacist before starting treatment.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Ask HR whether your employer included the anti-obesity benefit
Before searching formularies, ask your HR benefits team whether anti-obesity medications are included in your plan. Given New England's tightening GLP-1 market, do not assume the benefit is there — confirm it. If the employer excluded it, no PA will succeed.
- 2
Search Harvard Pilgrim's drug-lookup tool for your specific plan
Go to harvardpilgrim.org and use the formulary or drug-lookup tool with your member ID and plan. Search for 'Wegovy' or 'semaglutide 2.4 mg' to confirm tier, PA requirements, and quantity limits for your actual plan.
- 3
Work with your prescriber on prior authorization
If your plan covers Wegovy, your doctor will submit a PA to Harvard Pilgrim. Gather documentation: BMI measurement, relevant comorbidities, and evidence of lifestyle program participation. Track weight-loss progress before each renewal date to meet the reauthorization threshold.
Options if Harvard Pilgrim Health Care won't cover Wegovy
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Ozempic (semaglutide for T2D)
If you have type 2 diabetes, Ozempic (semaglutide) is broadly covered for T2D with PA across most commercial plans regardless of the anti-obesity benefit. Ozempic is not FDA-approved for weight loss and should not be prescribed for that indication.
NovoCare self-pay program
Novo Nordisk's NovoCare Pharmacy offers Wegovy at approximately $349/month for patients without coverage. An introductory rate of approximately $199/month applies to the 0.25 and 0.5 mg doses through December 31, 2026. List price is announced to drop to approximately $675/month effective January 1, 2027.
Compounded semaglutide
Compounded semaglutide is available without insurance for patients who cannot access covered Wegovy. See the Curex offer below. Compounded medications are not the same as Wegovy and have not been approved by the FDA.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
Harvard Pilgrim covers Wegovy for weight loss only on employer plans where the anti-obesity benefit was purchased. The plan does not publish drug-level Wegovy detail publicly, so the only way to confirm is through the drug-lookup tool at harvardpilgrim.org or by calling member services. ACA/individual plans generally exclude weight-loss GLP-1s. The New England market has been tightening — BCBS of Massachusetts ended weight-loss GLP-1 coverage in January 2026 — so verifying your current plan is essential.
New England has seen significant weight-loss GLP-1 pullbacks: Blue Cross Blue Shield of Massachusetts ended weight-loss GLP-1 coverage effective January 1, 2026, and New Hampshire Medicaid dropped GLP-1 obesity coverage the same month. These changes reflect regional cost pressure on insurers. Harvard Pilgrim has not publicly announced a comparable blanket exclusion, but the regional trend underscores why members should actively verify their current plan coverage rather than assuming it is unchanged from prior years.
Where the anti-obesity benefit is included in the employer plan, Harvard Pilgrim requires prior authorization with BMI 30 or higher (or 27 with a weight-related comorbidity such as hypertension, T2D, dyslipidemia, or sleep apnea), documented lifestyle program participation, and demonstrated weight-loss progress for renewal. Specific Harvard Pilgrim PA criteria are not publicly published — confirm current requirements with member services or your prescriber before submitting.
No. Medicare Part D cannot cover Wegovy for weight loss by statute — this is a federal rule applying to all plans including Harvard Pilgrim. Harvard Pilgrim Medicare Advantage plans can cover Wegovy for the cardiovascular risk-reduction indication in members with established CVD. The Medicare GLP-1 Bridge (launching July 1, 2026) provides weight-loss access at $50/month outside Part D for eligible beneficiaries — verify Bridge eligibility criteria with your prescriber.
No. New Hampshire Medicaid dropped GLP-1 obesity coverage effective January 1, 2026. Harvard Pilgrim members in NH on Medicaid therefore cannot access Wegovy for weight loss through Medicaid, though non-weight-loss FDA indications (such as the cardiovascular indication for members with established CVD) remain covered where applicable. Confirm current NH Medicaid drug policy through the NH DHHS website or Harvard Pilgrim member services.
Related Articles
Does Quartz Health Solutions Cover Wegovy? 2026 | Curex
Quartz Health Solutions covers Wegovy only where your employer opted into the anti-obesity benefit. Not publicly published — verify on Quartz's formulary.
Read moreDoes Geisinger Health Plan Cover Wegovy? 2026 | Curex
Geisinger Wegovy coverage is employer-dependent and unpublished. PA Medicaid dropped GLP-1 obesity coverage in 2026. How to verify.
Read moreDoes Group Health Cooperative Cover Wegovy? 2026 | Curex
Group Health Cooperative covers Wegovy only where your employer opted in. Wisconsin co-op — drug-level detail not public. Verify on GHC's drug-lookup tool.
Read moreDoes Security Health Plan Cover Wegovy? 2026 | Curex
Security Health Plan (Marshfield Clinic) covers Wegovy only where your employer opted in. Not publicly published — verify on the plan's drug-lookup tool.
Read moreDoes Fallon Community Health Plan Cover Wegovy? | Curex
Fallon covers Wegovy only where your employer opted in. New England is tightening — BCBS-MA ended GLP-1 coverage in 2026. Verify your plan.
Read moreDoes Harvard Pilgrim Health Care Cover Ozempic? 2026 | Curex
Harvard Pilgrim covers Ozempic for type 2 diabetes with prior auth, not weight loss. NE Point32Health plan; T2D unaffected by GLP-1 weight-loss cuts.
Read moreWhether or not Harvard Pilgrim Health Care covers Wegovy, there's a path that skips insurance
Harvard Pilgrim covers Wegovy for weight loss only where the employer opted in, and New England's GLP-1 coverage market has been tightening. For patients without a covered route, Curex offers compounded semaglutide from $49/mo (compounded tirzepatide from $149/mo) at getcurex.com/cl/glp — no insurance, no prior authorization. Compounded semaglutide is not the same medication as Wegovy. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Wegovy and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Harvard Pilgrim Health Care before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Wegovy and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.